RxDoctor Payments DataLook up a doctor →

Alexandria Schwab, NP

Primary Care · Bay City, MINPI 1194295477

Payments from drug & device makers

$10,135in general payments, 2019–2025

Across 649 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$990
  • Amgen$589
  • Novartis$460
  • GSK$433
  • plus $5K from 37 others

What the payments were for

  • Food & beverage$10,134100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,135 in reported general payments places this provider in the 95th percentile of 292 primary care providers in Michigan.

See all primary care providers in Michigan

Medicare billing

Part B allowed, 2024
$35,048
Medicare patients
112
Services billed
1,160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban46$52,798
OzempicSemaglutide27$49,602
MounjaroTirzepatide20$31,099
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$27,182
JardianceEmpagliflozin24$25,755
FarxigaDapagliflozin Propanediol24$17,326
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$12,265
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$9,439
KerendiaFinerenone11$8,181
EntrestoSacubitril/Valsartan11$7,473
Breo ElliptaFluticasone/Vilanterol14$5,470
Combivent RespimatIpratropium/Albuterol Sulfate11$5,433
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,457
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$4,263
Atorvastatin Calcium300$3,825

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$266$52,79846 claims
Novo NordiskOzempic$990$49,60227 claims
GSKTrelegy Ellipta, Breo Ellipta$433$32,65249 claims
Boehringer IngelheimJardiance, Combivent Respimat$138$31,18835 claims
Lilly USA, LLCMounjaro$1,103$31,09920 claims
AstraZenecaFarxiga, Breztri Aerosphere$397$29,59143 claims
BayerKerendia$384$8,18111 claims
NovartisEntresto$460$7,47311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 292 primary care providers in Michigan.

Other primary care in Bay City

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →